Sign up for our FREE Weekly Newsletter
Current Issue
Past Issue
News and Information for Medical Professionals
Search Diabetes In Control
 
 
Bookmark and Share | Print | Category | Home Previous | Next
This article originally posted 20 February, 2007 and appeared in  Issue 352
Drug-Eluting Stents Appear Superior to Bare Metal in Diabetics
Both paclitaxel- and sirolimus-eluting stents show "a trend toward more favorable outcome" in diabetics with occluded coronary arteries compared with bare-metal stents, Dutch investigators reported.
Dr. Patrick W. Serruys and colleagues at Erasmus Medical Center in Rotterdam analyzed 2-year outcomes of 708 patients with diabetes mellitus enrolled in the RESEARCH and T-SEARCH registries. One in four of the diabetics were insulin-dependent.
The patients received a bare-metal stent, a paclitaxel-eluting stent or a sirolimus-eluting stent to open occluded coronary vessels.
The investigators report that the relative risk for target vessel revascularization and major adverse events was not significantly different in the paclitaxel-eluting stent compared with the bare-metal stent, after adjusting for independent predictors of adverse events.

The paclitaxel-eluting stent had a non-significant lower incidence of target vessel revascularization and major adverse events compared with sirolimus-eluting stent in non-insulin-dependent diabetics at 2 years. The rate of adverse events was higher with sirolimus-eluting stent at 1 year.

The 2-year cumulative mortality was comparable in all three groups. However, mortality rate during the second year was 5.8% in the sirolimus-eluting stent group compared with 1.2% in the paclitaxel-eluting stent group (p = 0.007).

The investigators observed that the incidence of stent thrombosis was 4.4% in the sirolimus-eluting stent group compared with 2.4% in the paclitaxel-eluting stent group and 0.8% in patients who received bare metal stents. The higher mortality rate with sirolimus-eluting stent may be related to the increased incidence of stent thrombosis in patients treated with the sirolimus-eluting stent.

The Dutch team notes that, overall, "there was no significant difference between sirolimus-eluting stent and paclitaxel-eluting stent in each of the clinical endpoints, and neither in the non-insulin-dependent diabetes mellitus group, which are hypothesized to be better off with paclitaxel-eluting stent."

"The present study suffers from the inherent limitations of a non-randomized trial," Dr. Serruys' team notes. "More larger-scale and randomized trials are needed to elucidate the best treatment for patients with diabetes mellitus and the possible superiority of one drug-eluting stent compared to another, also taking into account the long-term adverse events like stent thrombosis," the Dutch investigators conclude.

As reported in the January issue of the European Heart Journal. However, the question of whether one drug-eluting stent is superior to the other remains unclear.

Eur Heart J 2007;28:26-32.

================================

Start your own walking program
New StepTracker Available at special prices. See the results of the Step Program Study.
http://www.diabetesincontrol.com/programs/steps/index.shtml
Purchase your own pedometers and receive the Steps to Health Program at no charge. http://www.rx4betterhealth.com/steptracker/
The Only Pedometer on the Market That Comes With a Program for Success!

================================

DID YOU KNOW:
What Prevents Doctors from Counseling Their Patients to Lose Weight, Exercise, Quit Smoking?: Ninety-nine percent of doctors believe that part of their job is to encourage their patients to live a healthier lifestyle, but only 20% actually do it. Research at the University of Haifa addresses the question: why not? See this week’s Item #6

 

Bookmark and Share | Print | Category | Home

This article originally posted 20 February, 2007 and appeared in  Issue 352

Past five issues: Issue 495 | Issue 494 | Issue 493 | Issue 492 | Issue 491 |

Diabetes In Control Advertisers

Print This Week's Newsletter
Download This Week's Newsletter
Newsletter is in Adobe format
If you don't haveAdobe Acrobat Reader , you can download it for Free here .

Free CE Available
CE Programs On Diabetes Available here



Text Advertisement


Search Articles On Diabetes In Control
Sign up for our FREE Weekly Newsletter
Current Issue
Past Issue
Privacy / Advertising With Us / Contact Us
Add us to your favorite news reader
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.